Janus kinase (JAK)-STAT6 pathway inhibitors that block eostaxin-3 expression were therefore suggested as a promising new therapeutic option in EoE (Cheng et al., 2016), but should also be explored in the context of FD. This evidence concerns the gene STAT6 and eosinophilic esophagitis.